Evidence map›Paper›PMID 40102145›Full record

ReviewThe journal of prevention of Alzheimer's disease2025

Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities.

Giovanni B Frisoni, Federica Ribaldi, Gilles Allali, Théophile Bieth, Andrea Brioschi Guevara, Stefano Cappa, Lisa Cipolotti, Kristian Steen Frederiksen, Jean Georges, Frank Jessen and 20 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Minor neuropsychological deficits and stage 2 of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Review
  7. Article
  8. The role of brain health and resilience in reshaping trajectories of late-life neuropsychiatric disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Giovanni B FrisoniMemory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva, Geneva, Switzerland. Electronic address: giovanni.frisoni@unige.ch.
Federica RibaldiMemory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva, Geneva, Switzerland.
Gilles AllaliLeenaards Memory Centre, Department of Clinical Neurosciences, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Théophile BiethInstitut de la Mémoire et de la Maladie d'Alzheimer, IM2A, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France.
Andrea Brioschi GuevaraLeenaards Memory Centre, Department of Clinical Neurosciences, University Hospital of Lausanne (CHUV), Lausanne, Switzerland; Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland.
Stefano CappaFederation of the European Societies of Neuropsychology (FESN) University Institute of Advanced Studies Pavia, Italy; IRCCS Istituto Auxologico Italiano, Milan.
Lisa CipolottiFederation of the European Societies of Neuropsychology (FESN), Switzerland.
Kristian Steen FrederiksenEuropean Academy of Neurology (EAN), Switzerland.
Jean GeorgesAlzheimer Europe, Switzerland.
Frank JessenDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany; Excellence Cluster Cellular Stress Responses in Aging-Related Diseases (CECAD), Medical Faculty, University of Cologne, Germany.
Giacomo KochDepartment of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS, 00179, Rome, Italy; Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy; Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), Ferrara, Italy.
Hugh MastersBrain Health Scotland United Kingdom.
Augusto J MendesMemory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva, Geneva, Switzerland.
Lutz FrölichEuropean Alzheimer's Disease Consortium, Switzerland.
Valentina GaribottoEuropean Association of Nuclear Medicine (EANM), Switzerland.
Oriol Grau-RiveraBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Federico E PozziClinica Neurologica, IRCCS San Gerardo dei Tintori, Monza, Italy.
Dorota ReligaEuropean geriatric medicine society (EuGMS), Switzerland; Karolinska Institutet, Stockholm, Sweden.
Ayda RostamzadehDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Lenny ShallcrossWorld Dementia Forum, London, UK.
Susan D ShenkinEuropean geriatric medicine society (EuGMS), Switzerland; University of Edinburgh, Edinburgh, Scotland United Kingdom.
Wiesje M van der FlierAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands; Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
Meike W VernooijEuropean Society of Neuroradiology (ESNR), Switzerland.
Leonie N C VisserDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Department of Medical Psychology, Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.
Jeffrey L CummingsChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV, USA.
Philip ScheltensAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands; EQT Life Sciences, Amsterdam, The Netherlands.
Bruno DuboisInstitut de la Mémoire et de la Maladie d'Alzheimer, IM2A, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France; Institut du Cerveau et de la Moelle Épinière, UMR-S975, INSERM, Paris, France Hôpital de la Pitié-Salpêtrière, France.
Elena MoroEuropean Academy of Neurology (EAN), Switzerland.
Claudio L A BassettiEuropean Brain Council, European Academy of Neurology, Swiss Brain Health Plan, Switzerland; Inselspital and Faculty of Medicine, University of Bern, Bern, Switzerland.
Miia KivipeltoDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland; Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK.

Funding

Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI Robert J. Fox, Jefferson Kinney · 2015 to 2026
$22.8M
Alzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9M
NIA NIH HHS R35 AG071476NIGMS NIH HHS P20 GM109025
6 · The paper itself

Abstract

A European Task Force has recently developed and published the concept and protocols for the setup of the innovative health offer of Brain Health Services for the secondary prevention of dementia and cognitive impairment (dBHS). dBHS are outpatient health care facilities where adult persons can find an assessment of their risk of developing cognitive impairment and dementia, have their risk level and contributing factors communicated using appropriate language supported by adequate communication tools, can decide to participate to programs for personalized risk reduction if at higher risk, and benefit from cognitive enhancement interventions. This health offer is distinct from that of currently active memory clinics. The ultimate aim of dBHS is to extend healthy life, free from cognitive impairment. Here, we (i) discuss the pertinent opportunities and challenges for those persons who want to benefit from dBHS, professionals, and wider society, (ii) describe the concepts, protocols, organizational features, and patient journeys of some currently active dBHS in Europe, and (iii) argue in favor of the business case for dBHS in Europe.

Indexed as

Cognitive DysfunctionDementiaSecondary PreventionEuropeHumansBrain health services (dBHS)DementiaPreventive healthcarePublic healthSecondary prevention

Identifiers

PMID40102145
PMCPMC12183968

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.